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Abstract
In recent years, several researches have showed that Buyang Huanwu Decoction (BHD) possesses multiple target points in the intervention
of diseases, and has same treatment effects on cerebrovascular diseases and cardiovascular diseases. But, there was no full report about the
mechanistic and material basis in Brain-Heart concurrent treatment. The objective of the present study was to examine the pharmacological
mechanism of traditional Chinese medicine in the intervention of coronary heart disease and stroke. We combined the HIT, PubChem, David
Database resource and the networked pharmacology method to ultimately find out BHD’s thirty-five potential brain-heart concurrent treatment
target points, and preliminarily reveal BHD’s material basis for treatment of cerebrovascular diseases and cardiovascular diseases. Finally, the
study provided new information with the guidance meanings.
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Introduction
Buyang Huanwu Decoction (BHD) was from Corrections of Medical Field· Discussion of Paralysis and Flaccid Paralysis, which was
written by Wang Qingren (1768-1831). A famous doctor in the Qing dynasty. BHD includes 200 g Astragalus mongholicus, 10 g Angelica tail,
7.5 g Root of common peony, 5 g lumbricus, 5 g Safflower, 5 g peach seed and 5 g Ligusticum chuanxiong Hort. with functions of tonifying Qi,
invigorating the circulation of blood and dredging collaterals. Usually, it was used to treat cerebrovascular diseases, such as ischemic stroke, qi
deficiency and blood stasis, cerebral infarction and etc (Zehong and Yinghui, 2006; Xiaoqing, 2005a). Besides, BHD had good treatment in
diseases like angina, obstruction of qi in the chest, hypertension, and congestive heart failure（Hongbin,et al 2005; Huijuan,2007). Based on
physiological and pathological research of cerebrovascular cardiovascular, the theory of Brain-Heart concurrent treatment had been put forward
according to clinical practices (Di and peng,et al 2013 ). It had been confirmed that BHD had exact curative effects on Brain-Heart concurrent
treatment, which was accorded with the theory of treating different diseases with same method in Traditional Chinese Medicine (TCM). Most of
the scholars thought that Qi deficiency and blood stasis were the foundation of stroke (Xiaoqing, 2005b; Yunke, 2006 ) and benefiting Qi for
activating blood circulation as the most fundamental method for curing the sequel of stroke (Meikui, et al 2002).There were also other researches
that showed that BHD’s treatment of disease was on multiple levels, meaning that BHD had multiple target points in the intervention of diseases
(Wanxia and Rongheng, 2008). So far, there was no full coverage about the molecular basis of BHD in Brain-Heart concurrent treatment.
Therefore, it is particularly important to conduct research of Buyang Huanwu Decoction (BHD)’s pharmaceutical effect mechanism and material
basis on molecular level. The study combined the HIT, PubChem, David Database resource and the networked pharmacology method to
ultimately find out a quick and accurate Database Resource Using Method for identifying the targets of drug actions. Also, BHD’s thirty-five
potential brain-heart concurrent treatment target points had been found out according to this method to offer theory basis for the research BHD’s
pharmaceutical effect mechanism and material basis.
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Materials and Methods
Data Resource (HIT Database, PubChem Database and David Database) and Search Method
HIT database
We logged on to HIT homepage (http://lifecenter.sgst.cn/hit/) and input each TCM herbs of BHD prescriptions. Thus, we got each TCM’s
main chemical component. For example, if we input herb “Root of common peony”, we get eight major components, i.e., paeonol, paeoniflorin,
acetic acid, catechin, (+)-catechin, (-)-catechin, gallocatechin and epigallocatechin. Then, “paeonol” would be taken as an example for illustrating
the detailed retrieval process.
PubChem database
We logged on to PubChem Homepage (http://www.ncbi.nlm.nih.gov/pccompound) and searched for “paeonol”. We got the paeonol’s CID
number (11092) from the site, and we linked back to PubChem homepage and clicked “chemical structure search” below “PubChem Tool”. From
the display, we clicked on “CID, SMILES, INCHI” below “identity similarity”, and input 11092 in the blank, unfold “option” menu. We chose
similarity greater than 90 and other options were default (Table 1). At last, we clicked “search” to enter next level (Haibo, et al 2012)..
On the basis of PubChem database results, there were 3129 results shown in Table 2. On the right side of webpage, we saw the item “Bio
Activity Experiments” under “Refine your results”. Then, we clicked “Bioassays Active (226)”, and got 226 main active ingredients. Next, we
clicked “BioActivity Analysis” under “Action on your results”, and finished target analysis for these 226 active components. The item of “target”
was the useful result we needed. We then clicked “download” to download the contents. In the downloaded file, data of “active compounds”
showed that results 0-35 were meaningful targets. Found with these meaningful targets was a corresponding “sequence GI used in assays”, and
these GI number was organised for the next step (Haibo, et al 2012). . After it, we found out all the corresponding GI number of main components
about herbs in BHD prescription and organised them for the next step.
David Homepage. We logged on to David homepage (http://david.abcc.ncifcrf.gov/summary.jsp) and clicked “upload” under “start analysis”. We
input all the GI numbers, chose “protein GI Accession” for “step 2”, chose “gene list” for “step 3”, then started search and observation of results
(Table 2). As shown in Table 2, we clicked “genetic association db disease class”, for pop up in another page. It can be found that there were
numbers of disease categories and the “neurological” and “cardiovascular” disease categories were our goal. So, we clicked the term “gene”.
Then we obtained all BHD’s targets acting on cerebrovascular diseases and cardiovascular diseases (CVD). Finally, we clicked “download file”
to completely organise the results. Until now, we totally finished the whole search session and got the aimed results.
Results
According to the analysis of obtained results, we totally got BHD’s sixty-eight targets for treating cerebrovascular diseases and eighty
targets for treating cardiovascular diseases (CVD). By comparison, we finally found out BHD’s thirty-five potential brain-heart concurrent
treatment target points shown in Table 1. After the comprehensive screening of databases and artificial comparisons, Brain-Heart concurrent
treatment target points of BHD were elaborated, and these targets were not only related to cerebrovascular diseases, but also associated with
cardiovascular diseases, which were the material basis for the detection of Brain-Heart concurrent treatment mechanism at the molecular level.
Such as tumour necrosis factor β (TNF-β), it had been reported that TNF-β had complicated biological activities, inducing IL-1, IL-6 and other 
cell factors, widely taking part in the inflammatory reaction, the growth and adjustment of immune system, and the interaction effect of
pro-inflammatory factor and anti-inflammatory cytokines, and playing an important role in the formation of atherosclerosis and autoimmune
diseases (Lie, et al 2011). Some other studies revealed
Table 1: Thirty five potential brain-heart concurrent treatment target points of BHD
Number Protein targets
1 Glutathione S-transferase mu 1
2 Aldo-keto reductase family 1, member B1 (aldose reductase)
3 Androgen receptor
4 Cytochrome P450, family 1, subfamily A, polypeptide 1
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5 Cytochrome P450, family 19, subfamily A, polypeptide 1
6 Aldehyde dehydrogenase 2 family (mitochondrial)
7 3-hydroxy-3-methylglutaryl-Coenzyme A reductase
8 Arachidonate 5-lipoxygenase
9 Solute carrier family 6
10 Neurotransmitter transporter, noradrenalin, member 2
11 Solute carrier family 6
12 Neurotransmitter transporter, serotonin, member 4
13 5-hydroxytryptamine (serotonin) receptor 2A
14 Adenosine A2a receptor
15 Macrophage migration inhibitory factor
17 Adrenergic, alpha-2A-, receptor
18 Peroxisome proliferator-activated receptor alpha
19 Prostaglandin-endoperoxide synthase 2
20 Cytochrome P450, family 2, subfamily C, polypeptide 19
21 Dopamine receptor D1
22 Glutathione S-transferase omega 1
23 Cytochrome P450, family 2, subfamily C, polypeptide 9
24 Solute carrier family 5 (choline transporter), member 7
25 Heat shock 70kDa protein 1A; heat shock 70kDa protein 1B
26 Cytochrome P450, family 3, subfamily A, polypeptide 4
27 Adrenergic, alpha-2C-, receptor
28 Tumour necrosis factor (TNF superfamily, member 2)
29 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
30 GNAS complex locus
31 Vitamin D (1,25- dihydroxyvitamin D3) receptor
32 Similar to Serine-protein kinase ATM
33 Cytochrome P450, family 1, subfamily A, polypeptide 2
34 Cytochrome P450, family 2, subfamily D, polypeptide 6
35 Estrogen receptor 1
36 Tumour protein p53
37 Peroxisome proliferator-activated receptor gamma
38 ATP-binding cassette, sub-family B (MDR/TAP), member 1
that TNF level in the patients with coronary heart disease had obviously risen, indicating that TNF played an important part in coronary heart
disease (Huanmei, et al 2009).The target TNF-β was one of the thirty-five targets in the above method, and it had been confirmed that it had close 
relationship with both cerebrovascular diseases and cardiovascular diseases, as one of the confirmed Brain-Heart concurrent treatment target
points, which verified the veracity of this networked pharmacology method for excavating targets. Except for some reported targets in Table1
from previous documents, there were also many targets with no deep study and report. Therefore, these target pathways would provide new
research directions for studying pharmaceutical effect mechanism and material basis of BHD in Brain-Heart concurrent treatment.
Table 2: Corresponding relations between targets, effective components and herbs
No. Targets Effective component Corresponding relation with drugs
1 Glutathione S-transferase 1 Isoimperatorin, isorhamnetin Angelica tail, Astragalus mongholicus
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2
Aldo-keto reductase family 1,
member B1(aldose reductase)
Paeonol, isorhamnetin, kaempferol Root of common peony, Astragalus,
mongholicus
3
Androgen receptor Paeonol, isorhamnetin, kaempferol Root of common peony, Astragalus
mongholicus
4
Cytochrome P450,family 1,
subfamily A, polypeptide1
Paeonol, isorhamnetin, kaempferol Root of common peony, Astragalus
mongholicus
5
Cytochrome P450,family19,
subfamily A, polypeptide1
Paeonol, isorhamnetin, kaempferol Root of common peony, Astragalus,
mongholicus
6 Aldehyde dehydrogenase2
family(mitochondrial)
Paeonol, kaempferol Root of common peony, Astragalus ,
mongholicus
7 3-hydroxy-3-methylglutaryl- Coenzyme A
reductase
Palmitic acid, palmitic acid Angelica tail, Ligusticum Chuanxiong
Hort
8 Arachidonate 5-lipoxygenase Isorhamnetin, kaempferol Astragalus, mongholicus
9
Solute carrier family 6 , member 2
(neurotransmitter transporter,
noradrenalin)
Thymol, o-cresol Ligusticum Chuanxiong Hort
10 Solute carrier family 6, member 4
(neurotransmitter transporter, serotonin)
o-cresol Ligusticum Chuanxiong Hort
11
5-hydroxytryptamine (serotonin) receptor
2A
Paeonol, kaempferol Root of common peony, Astragalus,
mongholicus
12
Adenosine A2a receptor o-cresol, isoimperatorin, angelicin,
paeonol, isorhamnetin, kaempferol
Ligusticum Chuanxiong Hort, Angelica
tail, Root of common peony, Astragalus,
mongholicus
13 Macrophage migration inhibitory factor
(glycosylation- inhibiting factor)
Isorhamnetin, kaempferol Astragalus, mongholicus
14 Adrenergic, alpha-2A-, receptor o-cresol Ligusticum Chuanxiong Hort
15 Peroxisome proliferator- activated receptor
alpha
Palmitic acid, palmitic acid , paeonol Ligusticum Chuanxiong Hort, Angelica
tail, Root of common peony
16
Prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and
cyclooxygenase)
o-cresol, isorhamnetin, kaempferol Ligusticum Chuanxiong Hort, Angelica
tail
17
Cytochrome P450, family 2, subfamily C,
polypeptide 19
Isoimperatorin, angelicin, z-ligustilide,
butylphthalide, paeonol, isorhamnetin,
kaempferol
Ligusticum Chuanxiong Hort, Angelica
tail
Root of common peony, Astragalus ,
mongholicus
18 Dopamine receptor D1 Isoimperatorin, angelicin, isorhamnetin,
kaempferol, paeonol
Angelica tail, Root of common peony,
Astragalus, mongholicus
19 Glutathione S-transferase omega 1 Juglone, isorhamnetin, kaempferol,
catechin, gallocatechin,
Epigallocatechin
Peach seed, Root of common peony,
Astragalus, mongholicus
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20 Cytochrome P450, family 2, subfamily C,
polypeptide 9
Paeonol, kaempferol Root of common peony, Astragalus
mongholicus
21 Solute carrier family 5, member 7 (choline
transporter)
Paeonol, isoimperatorin, angelicin Root of common peony, Angelica tail
22 Heat shock 70kDa protein 1A;
heat shock 70kDa protein 1B
Paeonol, kaempferol Root of common peony, Astragalus ,
mongholicus
23 Cytochrome P450, family 3,
subfamily A, polypeptide 4
Paeonol, catechin, gallocatechin,
epigallocatechin, isoimperatorin,
angelicin, isorhamnetin, kaempferol,
z-ligustilide
Ligusticum Chuanxiong Hort, Angelica
tail,
Root of common peony, Astragalus ,
mongholicus
24 Adrenergic, alpha-2C-, receptor o-cresol Ligusticum Chuanxiong Hort
25 Tumour necrosis factor
(TNF superfamily, member 2)
Isoimperatorin Angelica tail
26 Nuclear factor of kappa light
polypeptide gene enhancer in B-cells 1
z-ligustilide, paeonol, isorhamnetin,
kaempferol
Ligusticum Chuanxiong Hort, Rootof
common peony, astragalus, mongholicus
27 GNAS complex locus Isorhamnetin Astragalus, mongholicus
28 Vitamin D receptor
(1,25- dihydroxyvitamin D3)
Juglone, paeonol , catechin,
gallocatechin, epigallocatechin,
isorhamnetin, kaempferol
peach seed, Root of common peony
Astragalus mongholicus
29 Similar to Serine-protein kinase ATM
(Ataxia telangiectasia mutated) (A-T,
mutated) ataxia telangiectasia mutated
Kaempferol Astragalus mongholicus
30
Cytochrome P450, family 1,
subfamily A, polypeptide 2
Isoimperatorin, angelicin, isorhamnetin,
kaempferol, paeonol, z-ligustilide,
butylphthalide, thymol
Ligusticum Chuanxiong Hort, Angelica
tail
Root of common peony, Astragalus
mongholicus
31 Cytochrome P450, family 2,
subfamily D, polypeptide 6
Isorhamnetin, kaempferol Astragalus mongholicus
32
oestrogen receptor 1 Isorhamnetin, kaempferol,
isoimperatorin
Astragalus mongholicus, Angelica tail
33
Tumour protein p53 Juglone, paeonol, isorhamnetin,
kaempferol
Peach seed, Root of common peony,
Astragalus mongholicus
34 Peroxisome, proliferator- activated,
receptor gamma
Thymol, o-cresol, paeonol, kaempferol Ligusticum Chuanxiong Hort, Root of
common peony, Astragalus mongholicus
35 ATP-binding cassette, sub-family B
(MDR/TAP), member 1
Paeonol, isorhamnetin, kaempferol Root of common peony, Astragalus
mongholicus
Corresponding relations between targets, effective components and herbs perfectly reveal the effective specific location of main ingredients in
TCM. The corresponding relationship can not only associate targets with drug ingredients, but also can provide new references for specific access
mechanism study.
Discussion
In recent years, quick development of network pharmacology has provided a lot of valuable information for drug research. The information
was provided by HIT database, PubChem database, and David database, which not only have advantage of large amounts of data, but also have
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accurate and comprehensive characteristics. Through comprehensive utilisation of these three database resources, we can find the targets
corresponding with the effective composition of herbs quickly and accurately, and can complete the collection of information within a few hours
with low requests of computer equipment. This method can greatly improve the efficiency, and get more accurate and comprehensive information.
So, it is a kind of fast and effective method to find targets. According to traditional Chinese medicines, different diseases could be treated with
same method or herbs, and the point was neither the cause nor disease symptom, but the identification of same pathogenesis for different diseases.
So, different diseases with same pathogenesis could be treated with same methods or herbs. The thirty-five targets found in this research are the
material basis for BHD’s treatment of stroke sequelae and Brain-Heart concurrent treatment. Some reports showed that BHD’s treatment of
disease was at multiple levels, and this research has accorded active ingredients in BHD with the corresponding targets, offering new information
with great guiding significance for the material basis research of BHD. With in-depth study of compound preparations, detection of detailed target
points for effective components in compound preparation has become the main tendency. In future study, through full use of network
pharmacology methods and database resources, those data mining methods could be applied in the study of material basis and acting mechanism
to offer some potential supports for basic research of herbs material.
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